FORE Biotherapeutics has announced that two abstracts on its investigational therapy plixorafenib will be presented at the ...
Conference Call to discuss Updated Data from Part B of the DeFianCe Study March 26, 2025 8:00 AM ET. Company Participants. Douglas Onsi - President ...
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback